Edwards Lifesciences VP Donald E. Bobo, Jr. Sells 6,500 Shares

On February 13th, Donald E. Bobo, Jr., Vice President of Edwards Lifesciences Corporation (NYSE:EW), announced the sale of 6,500 shares of the company's stock. The shares were sold for an average price of $75.75, resulting in a total transaction value of $492,375.00.

After this sale, Mr. Bobo now holds 46,936 shares of Edwards Lifesciences, which are valued at approximately $3,555,402. This sale marks a 12.16% reduction in his ownership stake in the company. The details of this transaction were made public through a filing with the Securities and Exchange Commission (SEC).

Edwards Lifesciences Stock Performance

On the same day as the transaction, Edwards Lifesciences' stock experienced a slight increase, trading up by $0.14 to $75.96. The total trading volume for the stock was 4,771,399 shares, surpassing its average volume of 4,585,607 shares. Currently, the market capitalization of Edwards Lifesciences stands at $44.80 billion, with a price-to-earnings ratio of 10.96. Furthermore, the company has a P/E/G ratio of 3.64 and a beta of 1.10. The stock has demonstrated a 50-day moving average price of $72.51 and a 200-day moving average price of $69.36. Over the past year, the stock has reached a low of $58.93 and a high of $96.12.

Recent Earnings Report

Edwards Lifesciences recently published its quarterly earnings data on February 11th, showing an earnings per share (EPS) of $0.59. This figure surpassed analysts' expectations, which estimated an EPS of $0.55, thus exceeding consensus projections by $0.04. The company reported a net margin of 70.82% and a return on equity of 20.76%. Analysts predict that Edwards Lifesciences will achieve an EPS of 2.56 for the current fiscal year.

Institutional Investment Trends

Many institutional investors have recently adjusted their positions in Edwards Lifesciences. For instance, Vanguard Group Inc. increased its stake by 10.4% in the fourth quarter, now owning over 69 million shares valued at around $5.12 billion after acquiring an additional 6.5 million shares. Similarly, Wellington Management Group LLP raised its ownership by 5.3%, holding approximately 33.2 million shares worth $2.46 billion. Other firms, such as State Street Corp. and Geode Capital Management, have also made significant changes to their holdings. Currently, about 79.46% of Edwards' stock is owned by hedge funds and institutional investors.

Analyst Opinions

Edwards Lifesciences has received varying ratings from analysts. Wolfe Research downgraded the stock from a "peer perform" rating to "underperform" with a $60.00 price target. Conversely, Morgan Stanley increased their price target from $70.00 to $75.00, maintaining an "equal weight" rating. Stifel Nicolaus recently upgraded the stock from a "hold" rating to a "buy" rating, raising their price target from $75.00 to $90.00. Overall, there are currently mixed ratings, with one sell rating, fourteen hold ratings, and twelve buy ratings.

About Edwards Lifesciences

Edwards Lifesciences Corporation specializes in providing innovative products and technologies for structural heart disease and critical care monitoring. Their offerings include transcatheter heart valve replacement products and solutions for mitral and tricuspid valve disorders, primarily used in minimally invasive procedures.

sale, shares, transaction